Discovery Life Sciences is the global market leader in biospecimen analysis and procurement for the pharmaceutical, biotechnology and diagnostics industries. Discovery leverages deep scientific expertise and consultative services, combined with the largest repository of research-quality biospecimens—all available and processed for analysis—to accelerate the discovery, research, and development of novel biomarkers, drug candidates, and diagnostics.
Discovery Life Sciences has vast bioanalytics capabilities, consultative services, and deep scientific expertise to quickly bring innovative solutions to the most complex research questions.
We have the largest repository of research-quality biospecimens—over ten million—all available and processed for analysis. Our global logistical systems facilitate the most efficient specimen acquisition,
Our biospecimen catalog includes normal, suspect, and disease-state samples, comprising rare diseases and racially and ethnically diverse exemplars, with a particular emphasis in: oncology; cardiology; neurology; and infectious, inflammatory, and autoimmune diseases.
We are driven by science. Customers value our consultative, innovative approach that helps them overcome obstacles to reach a faster end result. We engage with our customers to achieve their goals, and that’s why we say we are “Science at Your Service™”.
We have the largest repository of research-quality biospecimens—over ten million—all available and processed for analysis. We obtain the specimens through our Discovery Partners®. This is a global, integrated network of more than 165 clinical sources in 25 countries on six continents.
Our Discovery Partners are the route to hundreds of thousands of patients to find the ideal attributes for even the most complex studies. We leverage this extensive network of hospitals, academic medical centers, blood banks, clinical laboratories, and community-based medical practices to locate the specific biospecimens that our researcher clients need to fulfill their protocol objectives.
The Discovery Partners platform benefits from our thought leadership in protocol assessment; complex protocol development; IRB/EC submissions; and human biospecimen project management, inventory management, distribution, and innovative, forward-looking biorepository practices.
Yes. We guarantee that the tissue we send meets the pathological, physical, and histological characteristics highlighted as important in advance by the client. If there is a discrepancy, we will replace the tissue at our cost. However, we do not guarantee results in extraction-based assays trying to detect various markers. We have a shared-risk policy for these projects – please inquire.
We specialize in custom and/or large procurement studies. Our experienced procurement team will work with you to design your project strategy and oversee tissue collection from start to finish. Our Discovery Partners® network can accommodate requests such as: biofluids (blood, urine, saliva, CSF, PBMC isolation), fresh tissue in custom media, matched pairs (frozen/FFPE, tumor/NAT), and multi-phase or longitudinal collections.
Discovery is committed to quality and integrity as an ISO 9001-certified company with CLIA-certified labs, stringent IRB and Ethics Committee compliance, and all required EU approvals and certifications. Navigating the new personal data protection regulations (both US and internationally) is a core competency.
Clinical Laboratory Improvement Amendments (CLIA), is a certification from the Centers for Medicare & Medicaid Services. The certification is to ensure quality laboratory testing performed on human specimen.
Click here or call 866-838-2798 to get started.
We work with our clients to ship their specimen to the standard and quality they desire. Frozen: Generally, we only ship frozen specimen Monday through Wednesday. All frozen shipments are insured and shipped on dry ice. FFPE and TMA: FFPE specimen and TMA’s are packaged in slide cases and clam shells for protection.